Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant androgen depletion in combination with vorinostat followed by radical prostatectomy for localized prostate cancer: total androgen-receptor gene expression targeted therapy (TARGET)

Next Previous
X
Search
Trial Profile

Neoadjuvant androgen depletion in combination with vorinostat followed by radical prostatectomy for localized prostate cancer: total androgen-receptor gene expression targeted therapy (TARGET)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bicalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Vorinostat (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms TARGET

    • Most Recent Events

    • 16 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 26 Jul 2013 Planned end date changed from 1 Jan 2100 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 19 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Jan 2100 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top